MR Imaging of Prostate Cancer in Radiation Oncology: What Radiologists Need to Know

References

• 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10–29.
  Google Scholar
• 2 Howlader N, Noone AM, Krapcho M, et al.. SEER cancer statistics review, 1975-2008. Bethesda, Md: National Cancer Institute, 2011.
  Google Scholar
• 3 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Prostate. In: AJCC cancer staging handbook. 7th ed. New York, NY: Springer, 2010; 525–538.
  Google Scholar
• 4 National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. Fort Washington, Pa: National Comprehensive Cancer Network, 2012.
  Google Scholar
• 5 D’Amico AV, Whittington R, Kaplan I, et al.. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37(5):1053–1058.
  MedlineGoogle Scholar
• 6 Kupelian P, Katcher J, Levin H, et al.. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997;3(2):78–87.
  MedlineGoogle Scholar
• 7 Zelefsky MJ, Wallner KE, Ling CC, et al.. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17(2):517–522.
  MedlineGoogle Scholar
• 8 Kuban DA, Tucker SL, Dong L, et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67–74.
  MedlineGoogle Scholar
• 9 Peeters ST, Heemsbergen WD, Koper PC, et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24(13):1990–1996.
  MedlineGoogle Scholar
• 10 Cellini N, Morganti AG, Mattiucci GC, et al.. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002;53(3):595–599.
  MedlineGoogle Scholar
• 11 Pucar D, Sella T, Schöder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008;18(1):87–97.
  MedlineGoogle Scholar
• 12 Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999;44(4):921–929.
  MedlineGoogle Scholar
• 13 De Meerleer G, Villeirs G, Bral S, et al.. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005;75(3):325–333.
  MedlineGoogle Scholar
• 14 van Lin EN, Fütterer JJ, Heijmink SW, et al.. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65(1):291–303.
  MedlineGoogle Scholar
• 15 Haider MA, van der Kwast TH, Tanguay J, et al.. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189(2):323–328.
  MedlineGoogle Scholar
• 16 Delongchamps NB, Rouanne M, Flam T, et al.. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int 2011;107(9):1411–1418.
  MedlineGoogle Scholar
• 17 Chen M, Dang HD, Wang JY, et al.. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008;49(5):602–610.
  MedlineGoogle Scholar
• 18 Fütterer JJ, Heijmink SW, Scheenen TW, et al.. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241(2):449–458.
  Google Scholar
• 19 Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25(1):146–152.
  MedlineGoogle Scholar
• 20 Boonsirikamchai P, Kaur H, Kuban DA, Jackson E, Hou P, Choi H. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. AJR Am J Roentgenol 2012;198(3):W228–W236.
  MedlineGoogle Scholar
• 21 Kundra V, Silverman PM, Matin SF, Choi H. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer. AJR Am J Roentgenol 2007;189(4):830–844.
  MedlineGoogle Scholar
• 22 Mirilas P, Skandalakis JE. Urogenital diaphragm: an erroneous concept casting its shadow over the sphincter urethrae and deep perineal space. J Am Coll Surg 2004;198(2):279–290.
  MedlineGoogle Scholar
• 23 Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001;219(3): 817–821.
  Google Scholar
• 24 Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243(1):28–53.
  Google Scholar
• 25 Fütterer JJ, Scheenen TW, Heijmink SW, et al.. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007;42(2):116–122.
  MedlineGoogle Scholar
• 26 Yuen JS, Thng CH, Tan PH, et al.. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004; 171(4):1482–1486.
  MedlineGoogle Scholar
• 27 Sala E, Akin O, Moskowitz CS, et al.. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006;238(3):929–937.
  Google Scholar
• 28 Sato C, Naganawa S, Nakamura T, et al.. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21(3):258–262.
  MedlineGoogle Scholar
• 29 Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004;20(4):654–661.
  MedlineGoogle Scholar
• 30 Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157(6):2323–2328.
  MedlineGoogle Scholar
• 31 Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007;63(3):335–350.
  MedlineGoogle Scholar
• 32 Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: from diagnosis to interventions. RadioGraphics 2011;31(3):677–703.
  Google Scholar
• 33 van Dorsten FA, van der Graaf M, Engelbrecht MR, et al.. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20(2):279–287.
  MedlineGoogle Scholar
• 34 Zakian KL, Eberhardt S, Hricak H, et al.. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging—initial results. Radiology 2003;229(1):241–247.
  Google Scholar
• 35 Westphalen AC, Coakley FV, Kurhanewicz J, Reed G, Wang ZJ, Simko JP. Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. AJR Am J Roentgenol 2009;193(3):W238–W243.
  MedlineGoogle Scholar
• 36 Barrett A, Dobbs J, Morris S, Roques T. Prostate. In: Practical radiation therapy planning. 4th ed. London, England: Hodder Arnold, 2009; 332–350.
  Google Scholar
• 37 Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005;63(3):800–811.
  MedlineGoogle Scholar
• 38 Kupelian PA, Willoughby TR, Meeks SL, et al.. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys 2005;62(5):1291–1296.
  MedlineGoogle Scholar
• 39 Chung PW, Haycocks T, Brown T, et al.. On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 2004;60(1):329–334.
  MedlineGoogle Scholar
• 40 Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007;69(2):419–425.
  MedlineGoogle Scholar
• 41 Kagan AR, Schulz RJ. Proton-beam therapy for prostate cancer. Cancer J 2010;16(5):405–409.
  MedlineGoogle Scholar
• 42 Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44(4):789–799.
  MedlineGoogle Scholar
• 43 Sanda MG, Dunn RL, Michalski J, et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12): 1250–1261.
  MedlineGoogle Scholar
• 44 Ohori M, Abbas F, Wheeler TM, Kattan MW, Scardino PT, Lerner SP. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 1999;161(2):500–504.
  MedlineGoogle Scholar
• 45 Ling CC, Humm J, Larson S, et al.. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47(3):551–560.
  MedlineGoogle Scholar
• 46 Heijmink SW, Scheenen TW, van Lin EN, et al.. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int J Radiat Oncol Biol Phys 2009;73(5):1446–1453.
  MedlineGoogle Scholar
• 47 Mizowaki T, Cohen GN, Fung AY, Zaider M. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 2002;54(5): 1558–1564.
  MedlineGoogle Scholar
• 48 Pouliot J, Kim Y, Lessard E, Hsu IC, Vigneron DB, Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004;59(4): 1196–1207.
  MedlineGoogle Scholar
• 49 Zelefsky MJ, Valicenti RK, Hunt M, et al.. Low-risk prostate cancer. In: Perez and Brandy’s principles and practice of radiation oncology. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2008; 1339–1483.
  Google Scholar
• 50 Frank SJ, Stafford RJ, Bankson JA, et al.. A novel MRI marker for prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008;71(1):5–8.
  MedlineGoogle Scholar
• 51 Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–1597.
  MedlineGoogle Scholar
• 52 Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001;28(3):555–565.
  MedlineGoogle Scholar